Web Results

BRISTOL-MYERS SQUIBB COMPANY v. APOTEX, INC. et al, No. 3 ...

law.justia.com/cases/federal/district-courts/new-jersey/njdce/3:2010cv05810/248908/142/

BRISTOL-MYERS SQUIBB COMPANY v. APOTEX, INC. et al, No. 3: 2010cv05810 - Document 142 (D.N.J. 2013) case opinion from the District of New Jersey ...

Case Project - American Antitrust Institute

www.antitrustinstitute.org/files/550c.pdf

Pan.Mult.Lit. Dec. 21,. 2004((No. MDL 1648). Page 84. In re Sorbates Direct ..... v. Bristol-Myers Squibb Co, et al, No. 01-CV. 11401, MDL 1413 (available at.

IN RE: DOW CORNING CORPORATION | FindLaw

caselaw.findlaw.com/us-6th-circuit/1304239.html

(95-2084); Bristol-Myers Squibb Co.; Medical Engineering Corporation ... E. Pitts, Jr. (argued), Sidley & Austin, New York City, for Bristol-Myers Squibb ... those actions to Chief Judge Pointer of the Northern District of Alabama. .... A.H. Robins Co. v. ... In re Pan Am Corp., 16 F.3d 513, 515 (2d Cir.1994) (“In re Pan Am Corp.

Long-Term Outcomes in the Second-Line Treatment of Chronic ...

www.ncbi.nlm.nih.gov/pmc/articles/PMC4428165/

Oct 13, 2010 ... Indeed, recently, it was demonstrated that the presence of E255K/V, Y253H, or F359C/V ... Bristol-Myers Squibb did not influence the content of the article, nor did the authors receive ... Baccarani M, Cortes J, Pane F, et al. ... Sprycel [ package insert] Princeton, NJ: Bristol-Myers Squibb Company; 2009. 33.

Blood Journal | European LeukemiaNet recommendations for the ...

www.bloodjournal.org/content/122/6/872

Aug 8, 2013 ... A US and Canadian Intergroup trial of dasatinib vs imatinib reported similar results. ... of the patients in whom previous TKI therapy failed, based on a company-sponsored, ... Pavlu et al updated the Hammersmith results for patients ..... as consultant and advisor of Novartis, Bristol-Myers Squibb, and Ariad; ...

The development of immunomodulatory monoclonal antibodies as a ...

www.sciencedirect.com/science/article/pii/S0163725814002174

Dec 1, 2014 ... Ipilimumab (Yervoy®, Bristol-Myers Squibb) and nivolumab (OPDIVO, .... However, initially its function was not fully understood (Brunet et al., 1987). .... Monoclonal antibodies that directly activate CD137 can co-stimulate and ..... 10.9 vs. 5.7%), and progression-free survival (PFS) (with medians of 2.76 vs.

Covington & Burling LLP | George F. Pappas

www.cov.com/en/professionals/p/george-pappas

Representation of Bristol-Myers Squibb in patent litigation in the District of New Jersey ... Bristol-Myers Squibb Company v. Dr. Reddy's Laboratories Ltd., et al.

Regular Article - Blood Journal

www.bloodjournal.org/content/123/15/2317.full.pdf

Development lab at Bristol-Myers Squibb) through the 2-year measurement, after which they .... SHAH et al. BLOOD, 10 .... Furthermore, regardless of imatinib resistance (resistance vs re- sistance or ..... Princeton, NJ: Bristol-Myers Squibb Company; 2013. 9. ... Baccarani M, Cortes J, Pane F, et al; European. LeukemiaNet.

Overall Survival and Long-Term Safety of Nivolumab (Anti ...

jco.ascopubs.org/content/early/2015/04/15/JCO.2014.58.3708.full

Apr 20, 2015 ... Consulting or Advisory Role: Bristol-Myers Squibb, ARIAD Pharmaceuticals .... Yang JC,; Hirsh V,; Schuler M,; et al. ... Kwak EL,; Bang YJ,; Camidge DR,; et al. ... (1999) B7-H1, a third member of the B7 family, co-stimulates T-cell ..... A Patient- Derived, Pan-Cancer EMT Signature Identifies Global Molecular ...

Linifanib Versus Sorafenib in Patients With Advanced ...

jco.ascopubs.org/content/33/2/172.full.pdf

Jan 10, 2015 ... Hongming Pan, Sir Run Run Shaw. Hospital ... e-mail: calincainap@yahoo.co.uk. ..... Cainap et al .... the linifanib arm (P .05) was increased ALT (4.8% v 2.2%). .... Novartis; Pei-Jer Chen, Bristol-Myers Squibb, Roche, Janssen.

More Info

Bristol-Myers Escapes $3.4B Apotex Suit Over Plavix Deal - Law360

www.law360.com

Mar 14, 2013 ... Bristol-Myers Squibb Co. and partner Sanofi-Aventis SA won a defense verdict Wednesday in a $3.4 billion ... The case is Apotex Inc. et al. v.

MICHAEL SEIDERS, Bristol-Myers Squibb Company — High-Level ...

www.unsgaccessmeds.org

Feb 26, 2016 ... MICHAEL SEIDERS, Bristol-Myers Squibb Company ..... George J. Schieber et al. , “Financing Global Health: Mission Unaccomplished,” Health ...

Differential effects of dosing regimen on the safety and efficacy of ...

www.ncbi.nlm.nih.gov

Jun 10, 2013 ... For example, Larson et al have shown the correlation of imatinib Cmin with both .... Sprycel<sup>®</sup>(dasatinib) [summary of product characteristics] Epernon: Bristol- Myers Squibb Company; 2012. 8. .... Baccarani M, Cortes J, Pane F, et al. ... et al. IRIS (International Randomized Interferon vs STI571) Study Group.